Literature DB >> 8640777

Inhibitory effects of activin on the growth and morpholgenesis of primary and transformed mammary epithelial cells.

Q Y Liu1, B Niranjan, P Gomes, J J Gomm, D Davies, R C Coombes, L Buluwela.   

Abstract

Activin is a member of the transforming growth factor beta superfamily, which is known to have activities involved in regulating differentiation and development. By using reverse transcription-PCR analysis on immunoaffinity-purified human breast cells, we have found that activin beta a and activin type II receptor are expressed by myoepithelial cells, whereas no expression was detected in other breast cell types. In examining 15 breast cell lines, we have found only four (HBL-100, MCF10-A, PMC-42, and BT 20) to be positive for activin beta a mRNA, whereas all expressed the activin type II receptor. Furthermore, we have found activin A to be a potent growth inhibitor of MCF- 7 cells (at 2 ng/ml), where it causes an arrest in G(1). Activin A does not appear to have an effect on the cell cycle of primary myoepithelial or luminal cells. However, we demonstrate that activin is an inhibitor of tubule formation by human mammary organoids in vitro. These are the first observations of activin and activin receptor in the normal human breast and in human breast cell lines and suggest a role for activin in mammary cell growth and morphogenesis.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8640777

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  26 in total

Review 1.  Estrogen responsiveness and control of normal human breast proliferation.

Authors:  E Anderson; R B Clarke; A Howell
Journal:  J Mammary Gland Biol Neoplasia       Date:  1998-01       Impact factor: 2.673

Review 2.  Tissue architecture and breast cancer: the role of extracellular matrix and steroid hormones.

Authors:  R K Hansen; M J Bissell
Journal:  Endocr Relat Cancer       Date:  2000-06       Impact factor: 5.678

Review 3.  TGF-beta signaling in mammary gland development and tumorigenesis.

Authors:  L M Wakefield; E Piek; E P Böttinger
Journal:  J Mammary Gland Biol Neoplasia       Date:  2001-01       Impact factor: 2.673

4.  Upregulated INHBA expression may promote cell proliferation and is associated with poor survival in lung adenocarcinoma.

Authors:  Christopher W Seder; Wibisono Hartojo; Lin Lin; Amy L Silvers; Zhuwen Wang; Dafydd G Thomas; Thomas J Giordano; Guoan Chen; Andrew C Chang; Mark B Orringer; David G Beer
Journal:  Neoplasia       Date:  2009-04       Impact factor: 5.715

Review 5.  The role of activin in mammary gland development and oncogenesis.

Authors:  Karen A Dunphy; Alan L Schneyer; Mary J Hagen; D Joseph Jerry
Journal:  J Mammary Gland Biol Neoplasia       Date:  2011-04-08       Impact factor: 2.673

6.  Hypoxia-induced nitric oxide release by luminal cells stimulates proliferation and uPA secretion of myoepithelial cells in a bicellular murine mammary tumor.

Authors:  Martin Alejandro Krasnapolski; Catalina Lodillinsky; Elisa Bal De Kier Joffé; Ana María Eiján
Journal:  J Cancer Res Clin Oncol       Date:  2015-02-17       Impact factor: 4.553

7.  DNA damage drives an activin a-dependent induction of cyclooxygenase-2 in premalignant cells and lesions.

Authors:  Colleen Fordyce; Tim Fessenden; Curtis Pickering; Jason Jung; Veena Singla; Hal Berman; Thea Tlsty
Journal:  Cancer Prev Res (Phila)       Date:  2009-12-22

8.  Overexpression of activin A in stage IV colorectal cancer.

Authors:  S Wildi; J Kleeff; H Maruyama; C A Maurer; M W Büchler; M Korc
Journal:  Gut       Date:  2001-09       Impact factor: 23.059

Review 9.  Differentiation and cancer in the mammary gland: shedding light on an old dichotomy.

Authors:  O W Petersen; L Rønnov-Jessen; V M Weaver; M J Bissell
Journal:  Adv Cancer Res       Date:  1998       Impact factor: 6.242

10.  Differential expression of follistatin and FLRG in human breast proliferative disorders.

Authors:  Enrrico Bloise; Henrique L Couto; Lauretta Massai; Pasquapina Ciarmela; Marzia Mencarelli; Lavinia E Borges; Michela Muscettola; Giovanni Grasso; Vania F Amaral; Geovanni D Cassali; Felice Petraglia; Fernando M Reis
Journal:  BMC Cancer       Date:  2009-09-09       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.